Le Lézard
Classified in: Health
Subjects: NPT, FDA

FDA Approves Breakthrough Drug to Treat Extensively Drug-Resistant Tuberculosis


RESEARCH TRIANGLE PARK, N.C., Aug. 14, 2019 /PRNewswire/ -- Today, the Food and Drug Administration (FDA) announced its approval of pretomanid, a new drug developed to treat Extensively Drug-Resistant Tuberculosis (XDR-TB) and treatment intolerant/non-responsive Multidrug-Resistant (MDR) TB. RTI International (RTI) scientist Dr. Doris Rouse and her team have collaborated closely with TB Alliance on the development of pretomanid for almost 20 years. TB Alliance is a non-profit product development partnership that RTI and Dr. Rouse helped to form in 2000. TB Alliance has negotiated license agreements enabling an affordable cost of pretomanid in low resource countries.

"We are seeing an increase in XDR-TB, and we need new weapons to attack it," Rouse says. "I've been in wards with patients that are so emaciated, they won't eat anything, they have fevers, they can't sleep. But with pretomanid, in a regimen that includes two other drugs, bedaquiline and linezolid, we see improvement within a few weeks. This new treatment will help people who have no other good option for a cure."

Pretomanid is only the third anti-TB drug approved by FDA in more than 40 years. Prior to the pivotal Nix-TB trial of pretomanid as part of a three-drug regimen with bedaquiline and linezolid (known as the BPaL regimen), treatment for XDR-TB required a two-year regimen and in South Africa, for example, only cured 2 to 22 percent of those receiving treatment. The six-month, all-oral BPaL regimen cured approximately 9 out of 10 participants of the XDR-TB patients in the trials conducted in South Africa.

Tuberculosis kills 1.6 million people a year ? more than 4,000 people a day ? and kills more people than any other infectious disease. XDR-TB is resistant to four of the main drugs, including injectable agents, currently used to treat drug resistant TB around the world.

With funding from the National Institute of Allergy and Infectious Diseases (NIAID), in 1999 Rouse and a team at RTI headed up the effort to identify potential new compounds for TB treatment. They identified and conducted due diligence on pretomanid, a compound developed by a small biotech, Pathogenesis.

TB Alliance acquired the license to pretomanid, then known as Pa-824, in 2002. RTI assisted TB Alliance in planning and managing the preclinical studies needed for development and preparing the successful Investigational New Drug (IND) application to FDA in 2005, leading to the start of clinical trials that year.

RTI has served as a regulatory contact for TB Alliance since the pretomanid IND was submitted to FDA in 2005.

"We've worked on this new drug for 19 years, and it hasn't always been an easy path," she added. "But as I've always said, 'One of the main ingredients for successful drug development is blessed stubbornness.' This public-private partnership is an excellent model for meeting unmet needs, especially those that are in low-resource countries that may not have the commercial attraction of other diseases."

TB Alliance is now targeting adoption and availability of pretomanid as part of the BPaL regimen in countries with a high unmet need for XDR-TB treatments.  

About RTI International
RTI International is an independent, nonprofit research institute dedicated to improving the human condition. Clients rely on us to answer questions that demand an objective and multidisciplinary approach?one that integrates expertise across the social and laboratory sciences, engineering, and international development. We believe in the promise of science, and we are inspired every day to deliver on that promise for the good of people, communities, and businesses around the world.  For more information, visit www.rti.org.

 

SOURCE RTI International


These press releases may also interest you

at 17:55
Original Notice On this page Why you should take note Investigation summary What you should do to protect your health Who is most at...

at 17:53
The Global Healthcare Accreditation (GHA) Program for Medical Travel Services has announced the release of COVID-19 Guidelines for Medical Travel Programs...

at 17:36
The Government of Canada remains concerned by the rise in youth vaping and is acting to address it. Following consultations on proposed changes, today the Honourable Patty Hajdu, Minister of Health, announced final regulations to prevent vaping...

at 17:35
McShane Construction Company is underway on the construction of a new senior living development, known as The Oaks at Algonquin. The firm was selected by Spectrum Retirement Communities to provide comprehensive construction services for the 166-unit...

at 17:19
Qualigen Therapeutics, Inc. ("Qualigen" or the "Company"), today announced it has entered into a definitive agreement with a single institutional investor for the purchase and sale for $8,000,000 of (i) 1,200,000 Common Shares, (ii) 780,198...

at 17:15
The "Global Active Pharmaceutical Ingredients (API) Market 2020-2026 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Region: Trend Forecast and Growth Opportunity" report...



News published on 14 august 2019 at 13:55 and distributed by: